[Management of XXXX in @entity1 with @entity177 ].

@entity1 @entity177 @entity1410 @entity6658
The treatments of @entity6658 ( @entity6658 ) were evaluated in 14 @entity1 (15 @entity1410 ) with @entity177 ( @entity177 ). We compared the data of our series with the data of co-operative study (1990) on @entity6658 . With regard to consciousness level (Neurological Grading, NG) and @entity1410 volume, significantly more serious cases were observed in @entity6658 with @entity177 than in @entity6658 of the co-operative study. In @entity6658 with @entity177 , mortality (40%) was significantly higher than that in @entity6658 of the co-operative study. However, the mortality rate was 0%, 0%, 20%, and 100% in NG1, 2, 3, and over 4b. The mortality rate was 0% in non-surgically treated cases with 0 to 30 ml of @entity1410 volume, and 0% in surgically treated cases with 10 to 50 ml of @entity1410 volume. These mortality rates were equal to those of the co-operative study with the same NG, and equal to those of the co-operative study with the same @entity1410 volume. With respect to functional prognosis, "good" (ADL1 and 2) resulted in 67% of non-surgically treated cases with NG1 to 2, and in 33% of surgically treated cases with NG3 to 4a. "Good" resulted in 33% of non-surgically treated cases with 0 to 30 ml of @entity1410 volume, and in 40% of surgically treated cases with 10 to 50 ml of @entity1410 volume. These morbidity rates were equal to those of the co-operative study with the same NG, and equal to those of the co-operative study with the same @entity1410 volume. Therefore, the high mortality in @entity6658 with @entity177 was suspected to be due to the fact that, in our study, there was a higher distribution of serious cases. These findings indicate that protection against enlargement of @entity1410 in the acute phase may bring about improvement of prognosis in @entity6658 with @entity177 .
